Skip to content

Author

Michael L. Whitfield

We have 2 of 24 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Abatacept Reduces CD319+ (SLAMF7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis.

Abatacept selectively modulates CD319/SLAMF7-expressing cytotoxic T cells and suppresses associated pro-fibrotic and pro-inflammatory cytokines, particularly in the fibroproliferative subtype, where CD319+ T cell reductions correlate with clinical improvement.

Mikel Gurrea-Rubio, Laura A. Cooney, Kohei Maeda et al. · 0 citations
Open access Jul 2026

Treatment Responses Alter Myeloid Activation in BRAF-Mutant Melanoma 2252856

This work establishes for the first time that BRAFi promotes myeloid-mediated induction of T cell activation, which is lost at resistance but can be rescued with the addition of CDDO- me, and provides the foundation for its potential use in combination therapies for melanoma.

Chen-Yu Wang, G. Torres, Helen C. Jarnagin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.